top of page
iPharmaCenter
News | Blogs | Healthcare | Consulting
Contact:
info@ipharmacenter.com
Home
Pharma
North America
US FDA Approvals
Canada Drug Healthcare News
APAC
China Drug Approvals
India Drug Approvals
APAC - Drug Approvals
Japan Drug Approvals | Healthcare
Europe
EMA News
LACAM
Brazil - Drug approvals
Healthcare News
US Healthcare News
US Payer News
APAC - Healthcare News
Europe Healthcare News
Lacam Healthcare News
Healthcare Policies
Disease News
Immunology
Oncology
Infections_Vaccines
Cardiovascular
Kidney Diseases
Metabolic Diseases
Women Health
Neurology
Conferences
Others
COVID-19
Contact
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Log in / Sign up
ipharmaservices
Jan 7
Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter
ipharmaservices
Jan 7
China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter
ipharmaservices
Dec 7, 2024
HUTCHMED and Innovent Announce Conditional Approval of Fruquintinib and Sintilimab Combination for Advanced Endometrial Cancer in China | iPharmaCenter
ipharmaservices
Dec 7, 2024
HUTCHMED Announces Continued Inclusion of Savolitinib in China’s National Reimbursement Drug List at Current Terms | China NRDL 2024 | iPharmaCenter
ipharmaservices
Dec 7, 2024
China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter
ipharmaservices
Oct 14, 2024
AstraZeneca and Daiichi Sankyo’s drug, Enhertu approved in China for HER2-mutant mNSCLC | iPharmaCenter
ipharmaservices
Aug 24, 2024
China's NMPA Grants Approval for Padcev (Enfortumab Vedotin) for Advanced Urothelial Cancer | iPharmaCenter
ipharmaservices
Aug 13, 2024
Enhertu Receives Conditional Approval in China for Advanced HER2-Positive Gastric Cancer | iPharmaCenter
ipharmaservices
Jul 8, 2024
HUTCHMED's NDA for Tazemetostat in China Receives Priority Review for Relapsed/Refractory Follicular Lymphoma | iPharmaCenter
ipharmaservices
Jul 2, 2024
Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter
ipharmaservices
Jun 26, 2024
China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter
ipharmaservices
May 13, 2024
China Drug Approvals | 2024 | iPharmaCenter
ipharmaservices
Dec 31, 2023
China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter
ipharmaservices
Mar 16, 2023
China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter
ipharmaservices
Dec 28, 2022
China Healthcare News | Drug News | iPharmaCenter
bottom of page